Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

InterMune Launches Esbriet in Germany At Better-Than-Expected Price

This article was originally published in The Pink Sheet Daily

Executive Summary

German pricing for InterMune's IPF drug Esbriet surprises on the upside, but will it last?
Advertisement

Related Content

Biogen Idec Buys Stromedix, Bringing IPF Candidate Full Circle
Grunenthal CEO Claims German Reimbursement Hurdle Is Fair, As Pain Drug Palexia Rolls Out Across Europe
Intermune’s Esbriet Flops In Front Of IQWiG
With Its Economy Struggling, Spain Launches Second Cost-Cutting Exercise In Two Years
New German Reimbursement Process Splits Opinion Ahead Of First Assessments
New German Reimbursement Process Splits Opinion Ahead Of First Assessments
BMS Bets On Amira's IPF Drug In $325M Acquisition
Actelion Management Re-Shuffle Reflects Continued Activist Pressure

Topics

Advertisement
UsernamePublicRestriction

Register

PS072768

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel